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SION: Resource use and cost increase as the severity of PD
worsens. The most signiﬁcant resource use increases occur when
patients reach HY4 due to mounting disability resulting in
increased hospitalisation and combination drug therapy.
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COST AND USE OF PARKINSONISM-INDUCING DRUGS
AMONG MEDICARE BENEFICIARIES
Noyes K, Liu H, Holloway RG
University of Rochester Medical Center, Rochester, NY, USA
OBJECTIVES: Drug-induced parkinsonism (DIP) is an akinetic-
rigid syndrome induced by pharmacologic agents that can be dif-
ﬁcult to distinguished from idiopathic Parkinson’s disease (PD).
The medications potentially inducing parkinsonism include 
neuroleptic drugs, non-neuroleptic drugs, selective serotonin
reuptake inhibitors (SSRI), and catecholamine-depleting agents
(CDA). Here we examine the use of parkninsonism-inducing
drugs among Medicare beneﬁciaries and estimate the economic
burden of DIP. METHODS: We used the community-dwelling
population of 1992–2000 Medicare Current Beneﬁciary Survey
(MCBS) participants (97,999 subject-years). Bivariate compar-
isons were used to determine differences in the use of PD-
inducing drugs between the beneﬁciaries with and without 
PD. Using multivariate model, we estimated the effect of PD-
inducing drug use on the total medical expenditures. RESULTS:
Among all MCBS beneﬁciaries, 1.63% reported having PD,
8.31% used PD-inducing drugs, and 0.93% used both anti-PD
and PD-inducing drugs in a given year. Neuroleptic drugs were
the most commonly used drugs inducing PD (53.82%), followed
by the SSRI (41.45%), non-neuroleptic drugs (15.27%), and
CDA (2.23%). More people with self-reported PD used PD-
inducing drugs than people without PD (14.11% vs. 8.21%, p
< 0.001). Among beneﬁciaries using both anti-PD and DIP drugs,
65.63% used neuroleptic medications (83.21% for people not
taking anti-PD medications, p < 0.001), 30.00% used non-
neuroleptic drugs (13.28%, p < 0.001), and 35.16% used SSRI
(18.59%, p < 0.001). After adjusting for personal characteristics
and comorbidities, the total annual medical costs were signiﬁ-
cantly higher in PD patients with psychiatric problems who were
using neuroleptic drugs compared to other beneﬁciaries with 
psychiatric problems ($12109 vs. $10032, p < 0.001). CON-
CLUSIONS: More patients with self-reported PD are taking
medications known to potentially cause DIP compared to
Medicare beneﬁciaries without PD. The neuroleptic medications
are the most common PD-inducing drugs among elderly.
Although more research is needed, it is likely that DIP medica-
tions are contributing to the economic and health burden of
parkinsonism in Medicare beneﬁciaries.
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OBJECTIVES: To establish and analyse treatment satisfaction
and principal causes which result in termination of drug treat-
ment of Parkinson’s Disease (PD) in Russia. METHODS: The
retrospective analysis was carried out for treatment which
patients received. In the analysis, 241 patients with PD (male:
127, female: 114; mean age: 66.1 ± 7.5 years, duration of
disease: 5.2 ± 3.2 years) have been included. RESULTS: Major-
ity of patients received two or three drugs; 160 patients accepted
levodopa (mean dose: 612.0 ± 327.7mg daily); 105 patients
accepted anticholinergics such as trihexyphenidyl (mean dose:
5.0 ± 2.0mg); 83 patients accepted amantadine (mean dose:
253.9 ± 72.1mg); 41 patients accepted dopamine agonist such
as pramipexole (mean dose: 2.4 ± 1.0mg); and 35 patients
accepted selegiline (mean dose: 9.1 ± 3.2mg). Adverse events
resulted in termination of treatment more often for anticholin-
ergics (n = 32), less often for levodopa (n = 8), amantadine (n =
5) and pramipexole (n = 4). Insufﬁcient efﬁcacy was the most
often cause of end in treatment by trihexyphenidyl (n = 21),
selegiline (n = 17), amantadine (n = 15), and rare reason of end
of treatment by levodopa (n = 3), pramipexole (n = 2). High cost
of drugs was the most often reason of pramipexole (n = 27) can-
cellation and only one case led to cancellation of levodopa. In
other cases, patients were satisﬁed with the treatment. In Russia,
mean daily dose of levodopa costs about US$0.9, pramipexole—
US$3.96, selegiline—US$0.88, amantadine—US$0.05 and tri-
hexyphenidyl—US$0.02. CONCLUSIONS: Principal causes of
the termination of drug treatment of PD were adverse events,
insufﬁcient efﬁciency, and high cost. Reduction of cost of treat-
ment of dopamine agonists such as pramipexole could lead to
increase in number of PD patients who would continue to get
treated in Russia.
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OBJECTIVES: This retrospective study quantiﬁes the prevalence
of insomnia among patients with chronic obstructive pulmonary
disease (COPD) from a large outpatient database. COPD is an
umbrella term for the lung disease category associated with
airﬂow obstruction, which includes emphysema, chronic bron-
chitis, and chronic asthma, either alone or in combination.
METHODS: Data from April, 1996 to September, 2003 on
patients with a diagnosis of COPD (ICD-9 codes 491.2, 492.0,
492.8, 493.2, and 496) were extracted from the GE Medical
Systems database—a large, outpatient, multipractice electronic
database system with input from over 2000 practicing physicians
in 26 US states. The insomnia cohort was deﬁned as patients
having either a diagnosis consistent with insomnia (ICD-9 codes
307.4x [x = 1–2, 9] and 780.5x [x = 0, 2] or a prescription for
insomnia medication. Demographic characteristics, comorbid
conditions, and concomitant medications were evaluated.
RESULTS: A total of 5,777 (21.4%) of 27,052 patients in the
COPD cohort were identiﬁed as having a diagnosis and/or being
treated for insomnia, compared with 7.2% of the non-COPD
patients. CONCLUSIONS: This exploratory analysis revealed
that patients with COPD in this large outpatient database were
diagnosed with and/or treated for insomnia almost three times
as frequently as those patients not having a diagnosis of COPD.
These data suggest that insomnia is a common and clinically
important comorbidity associated with COPD. The nature of
this association should be further investigated with a well-
designed prospective study, and treatments for insomnia related
to COPD need to be examined in greater detail.
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OBJECTIVE: To examine a medical records database to deter-
mine the prevalence of insomnia in patients with a history of
drug dependence or abuse. METHODS: Data from April, 1996
to September, 2003 on patients with a diagnosis of drug depen-
dence or abuse (ICD-9 code 303.9, 304–305 [except tobacco use,
305.1]) were extracted from the GE Medical Systems database—
a large outpatient database with input from over 2000 practic-
ing physicians. The insomnia cohort was deﬁned as patients
having either a diagnosis consistent with insomnia (ICD-9 codes
307.4x [x = 1–2, 9] and 780.5x [x = 0, 2]) or a prescription 
for insomnia medication. Demographic characteristics, comor-
bid conditions, and concomitant medications were evaluated.
RESULTS: A total of 13,861 patients in the database constituted
the population with drug dependence or abuse, and 2,479
(17.9%) of these composed the insomnia cohort. This insomnia
prevalence rate was more than twice that in the population
without reported drug abuse or dependence (7.4%; 115,487 of
1,567,751). Alcohol abuse was the most prevalent type of drug
dependence or abuse diagnosed in the insomnia cohort. The most
frequently reported comorbidities were depressive disorders
(32.4%), neurotic disorders (28.6%), and other unspeciﬁed dis-
orders of the back (23.4%). Analgesics (70.3%), psychothera-
peutics (81.1%), and anti-infective agents (61.4%) were among
the most common concomitant medications. CONCLUSIONS:
Patients with drug dependence or abuse were more than twice
as likely to have a diagnosis or prescription for insomnia med-
ication compared with patients without drug dependence or
abuse. The insomnia cohort had a high rate of comorbidities and
prescriptions for concomitant medications. These data suggest
that insomnia is a common comorbid problem in patients with
diagnosed histories of drug dependence or abuse. Since this spe-
ciﬁc population has unique issues and concerns related to use 
of prescription sedative hypnotic medications, further studies
examining safe, nonaddicting, and effective therapies for comor-
bid insomnia should be pursued.
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OBJECTIVES: Although the clinical beneﬁts of insomnia phar-
macotherapy have been studied, no systematic assessment of the
economic value has been published. This study assessed the cost
effectiveness of longer-term therapy with eszopiclone for chronic
primary insomnia in adults. METHODS: A decision analytical
model was developed on the basis of the results of a six-month
placebo-controlled trial, which demonstrated that eszopiclone 3
mg signiﬁcantly improved sleep and daytime function measures
versus placebo in adults with primary insomnia. These data were
supplemented with quality-of-life and cost data from published
literature and claims databases. Patients were classiﬁed as either
recovered or not recovered from insomnia based upon a com-
posite index of eight sleep and daytime function measures col-
lected during the trial. RESULTS: Compared to non-recovered
patients, patients classiﬁed as recovered had lower monthly costs
($866 vs. $1172) and higher quality-adjusted-life-year [QALY]
weight (0.8413 vs. 0.7644). Signiﬁcantly more treated patients
(versus placebo) recovered from insomnia (all p-values < 0.001).
At study termination, eszopiclone patients were 2.5 times more
likely to have recovered than placebo. Six-month eszopiclone
treatment was projected to reduce direct and indirect costs by
$311 and $208 per patient, respectively. Eszopiclone adminis-
tration was associated with a cost of $669 per patient. Overall,
six-month eszopiclone use was associated with a net cost increase
of $150 and a net QOLY gain of 0.0092 per patient. Conse-
quently, the incremental cost associated with eszopiclone 
was approximately $16,300 per QALY gained ($150/0.0092). 
Sensitivity analyses using a variety of scenarios conﬁrmed that
eszopiclone costs less than $50,000 per QALY gained. CON-
CLUSIONS: In this analysis, eszopiclone treatment was cost-
effective with costs per QALY gained within an acceptable range.
This result derives primarily from the beneﬁt observed in the clin-
ical trial that patients treated with eszopiclone were 2.5 times
more likely to recover from insomnia.
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OBJECTIVES: To develop a budget impact model estimating
potential costs of adding new drugs to the formulary using
medical claims and clinical trial data using a case study of eszopi-
clone, an insomnia medication awaiting approval. METHODS:
A 3-step process estimated the costs of treating insomnia using
eszopiclone and other insomnia agents: 1) Insomnia drug efﬁ-
cacy was estimated from published literature on marketed drugs
and from clinical trial reports of eszopiclone. Prior to summa-
rizing trial data, adjustments were made for the different char-
acteristics of each clinical trial (i.e., size, location, patient
characteristics); 2) A multiple regression model was then applied
to the MarketScan claims data (from 85,832 insomnia patients)
and to the clinical trial efﬁcacy data in order to estimate a rela-
tionship between medical expenditures and treatment efﬁcacy.
Patient-reported total sleep time was the primary efﬁcacy
measure, and ﬁve other sleep variables (patient-reported latency
and awakenings, PSG latency, sleep efﬁciency, and wake time
after sleep onset were included in the model; 3) Eszopiclone
expenditures (premium pricing assumed) were estimated by mul-
tiplying eszopiclone efﬁcacy estimates by the regression-based
estimates of expenditures. The regression model additionally
accounts for the impact of other demographics and clinical char-
acteristics that inﬂuence expenditures. A budget impact model
that could be used for any given health plan was then developed.
RESULTS: For a health plan with 100,000 members, the model
estimated that use of eszopiclone decreased annual insomnia
treatment costs by $498,204 using the default efﬁcacy endpoint,
total sleep time. Results were consistent regardless of which efﬁ-
cacy endpoint was used. CONCLUSIONS: Using this modeling
approach, use of eszopiclone is estimated to substantially
decrease annual treatment costs for insomnia patients. The mod-
eling approach used represents an alternative and potentially
effective way of estimating the impact of medications pending
marketing approval.
